Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE

Orion Porfolio Solutions LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 33.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 473,044 shares of the biopharmaceutical company’s stock after selling 236,206 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Pfizer were worth $12,053,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Fiduciary Alliance LLC grew its holdings in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pfizer during the 3rd quarter worth $3,019,000. Money Concepts Capital Corp grew its stake in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares in the last quarter. Vista Investment Partners LLC increased its holdings in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. raised its stake in Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after buying an additional 47,319 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday. Barclays assumed coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Finally, Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.05.

Pfizer Price Performance

Shares of PFE opened at $26.63 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a 50-day simple moving average of $26.26 and a 200-day simple moving average of $25.46. The company has a market capitalization of $151.43 billion, a price-to-earnings ratio of 19.58 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider?trading case involving SAC Capital, closing a long?running legal dispute and delivering a modest one?time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP?1 obesity program and its oncology pipeline — a bullish catalyst for longer?term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self?driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near?term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long?term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP?1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.